Adult ADHD with anxiety: the ten US physicians who manage it do not refer, and six treat the anxiety first
Of the ten US physicians on the panel who manage adult ADHD with comorbid anxiety, none refers the patient straight out: six treat the anxiety first, and nine said evidence that one daily medicine improved both conditions would make them treat the ADHD themselves (September 2026).
- Who was asked
- US physicians, 198 clones, US
- When
- September 2026 (fielded 28 September 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question is how often physicians refer adult ADHD with anxiety. On this panel that figure is carried by physicians who sit outside the ADHD pathway, so the study is split on whether the physician manages these patients at all, and that group is reported as counts.
Section 01: What the panel said
- #
6
Not one of the ten physicians who manage this patient refers it straight out.
base 10
- #
0
What holds them back is the diagnosis and the anxiety, not the referral boundary.
base 10
- #
9
Comorbidity evidence moves the intent. What they ask for is a guideline.
base 10
- #
182
Whether this patient is referred depends on whether the physician manages these patients at all, not on the patient.
base 198 · contrast
Not one of the ten physicians who manage this patient refers it straight out.
02What is the first thing a buyer should take from this?
Almost every physician on this panel says they refer adult ADHD with significant anxiety to psychiatry: 182 of the 188 who do not manage these patients themselves. That figure is about the panel, not about the pathway, because most of those physicians are dermatologists, cardiologists, oncologists and gastroenterologists for whom referral is simply correct practice.
The physicians who do manage this patient behave differently. Of the ten on this panel who personally manage adult ADHD alongside significant anxiety, not one refers the patient straight out. Six treat the anxiety first and leave the ADHD for later, and the other four assess in the room and then decide.
03Where does the answer change, and for whom?
It changes on whether the physician carries the patient at all, and the reason given moves with it. Among the 188 who do not manage these patients, 186 name specialist scope as the reason they would not treat the ADHD themselves. Among the ten who do, nobody names scope: six name diagnostic uncertainty, and the rest name the risk of making the anxiety worse.
These ten are primary care physicians, and several describe managing this patient because psychiatry is out of reach rather than because they set out to. In a fifteen to twenty minute appointment, anxiety and adult ADHD present alike, and telling them apart is the work they say they cannot fit in.
04What moves the decision, and what does not?
Told that strong evidence existed in adults with both conditions showing one daily medicine improved ADHD and anxiety together, nine of the ten said they would treat the ADHD directly rather than defer it. That is close to unanimous, and the question describes a favourable result, so it should be read as willingness under a good premise rather than as a forecast of prescribing.
Their own reasoning points at the gap. Asked what evidence they actually want, four of the ten name guidelines and protocols, and in their answers they describe waiting for guideline inclusion and for coverage before they use something new. The trial result opens the door. The guideline is what they say gets them through it.
05What would a brand manager do with this?
- Treat the patient who has already tried anxiety treatment as the opening, not the newly presenting one. All ten said they would be likely to treat the ADHD themselves in that case, against five of ten where the anxiety has no formal diagnosis. This is a reading of the pattern, not something the panel was asked to recommend.
- Aim the first wave of evidence at telling the two conditions apart, not at efficacy alone, since that is the barrier these physicians name for themselves.
- Assume guideline and formulary work sits on the critical path rather than after it. Stated willingness here ran well ahead of what these physicians said they would actually prescribe.
Section 06: What they said, and the interview line it rests on
“Being in a rural clinic where we don't have the resources to refer every mental health patient to psychiatry, I've had to get comfortable managing things myself. If there were strong evidence showing that a once-daily ADHD medication actually improved both ADHD and anxiety, I would be much more inclined to treat the ADHD directly right off the bat.”
Predicted from this line in the interview
“And we just don't have enough resources to send all of those patients to psychiatry, so kind of like with diabetes, I just had to get comfortable.”
Section 07: How much should you trust this?
What we would defend
- Not one of the ten physicians who manage this patient refers it straight out.
- What holds them back is the diagnosis and the anxiety, not the referral boundary.
- Comorbidity evidence moves the intent. What they ask for is a guideline.
What we would not
- The evidence question describes a medicine that improves both conditions, which is a leading premise: near-unanimity on it measures willingness, not what would actually be written.
- The panel holds no psychiatrists and is weighted to dermatology, so the large majority who refer sit outside the ADHD pathway and their referral is correct practice, not a barrier.
The main limitation
Ten physicians on this panel manage the patient in question, so every figure about them is a count and none of them is a market estimate.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Manage these patients | 10 |
| Do not manage them | 188 |
Question wording as fielded
- Do you personally manage adult patients with ADHD symptoms alongside significant anxiety or comorbid generalized anxiety disorder or social anxiety disorder?
- How would you describe your confidence in distinguishing adult ADHD symptoms from anxiety symptoms when they overlap?
- Thinking about that same new 2026 trial evidence, which barriers do you believe it could realistically change for you?
- What is the main reason you would choose not to treat the ADHD yourself in that situation?
- What kind of evidence or reassurance would most increase your willingness to treat the ADHD yourself rather than defer, refer, or treat anxiety alone?
- If you had strong clinical evidence in adults with ADHD and comorbid anxiety showing a once-daily ADHD medicine improved both ADHD and anxiety symptoms, how would that change what you would be most likely to do?
- How likely would you be to treat the ADHD yourself for each of the following situations?
- When an adult patient presents with ADHD symptoms alongside significant anxiety or comorbid generalized anxiety disorder or social anxiety disorder, what do you most often do first?
- Which of these concerns affect your decision when ADHD symptoms and significant anxiety appear together?
What was not asked, and why
We did not ask about any named medicine, brand or price, and we did not ask these physicians to estimate how often this patient reaches them.
What changed from the obvious question
The obvious question is how often physicians refer adult ADHD with anxiety. On this panel that figure is carried by physicians who sit outside the ADHD pathway, so the study is split on whether the physician manages these patients at all, and that group is reported as counts.
Fielded through Ask Brox on 28 September 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read